Aristada is the brand name for aripiprazole lauroxil, a long-acting injectable prodrug of aripiprazole. It was approved by the FDA in 2015 for schizophrenia and is unusual among LAIs in offering several dosing intervals — from every month to every 6 weeks to every 2 months — depending on the dose chosen. A separate companion product, Aristada Initio, was approved in 2018 to shorten the oral overlap requirement at initiation.
Aristada is a long-acting injectable aripiprazole prodrug offering flexible dosing intervals — monthly, every 6 weeks, or every 2 months — with a separate initiation product (Aristada Initio) that can replace the standard 21-day oral aripiprazole overlap.
How aripiprazole lauroxil works
Aripiprazole lauroxil is a prodrug: it is not active itself. After injection, enzymes in the body slowly cleave the lauroxil group, releasing N-hydroxymethyl aripiprazole, which is further converted to aripiprazole — the same active drug as in oral Abilify and Abilify Maintena. The prodrug formulation is what allows the slow, predictable release.
Once aripiprazole reaches the brain, it acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and an antagonist at serotonin 5-HT2A — the same mechanism as oral aripiprazole.
Dosing options
Aristada is unique in offering multiple dosing intervals:
- Monthly dosing at lower strengths
- Every 6 weeks at a middle strength
- Every 2 months at the highest strength (the longest interval available among aripiprazole LAIs)
The choice is between dose strength and dosing interval — patients on the highest dose can get just 6 injections a year. The right combination is decided by the prescriber based on response, tolerance, and patient preference.
Initiation: the standard 21-day oral overlap
The standard initiation of Aristada requires 21 days of oral aripiprazole after the first injection, similar to other depot products. During this period, the depot is slowly being released and oral medication maintains symptom control.
Aristada Initio: a one-day overlap option
For patients in whom 21 days of oral medication is impractical (acute hospitalisation, very poor adherence), Aristada Initio offers an alternative. Aristada Initio is a fast-releasing nanocrystal form of aripiprazole lauroxil that, when given alongside a single oral aripiprazole dose, achieves therapeutic blood levels within days. The standard initiation regimen with Aristada Initio is:
- One injection of Aristada Initio
- One oral dose of aripiprazole on the same day
- One injection of standard Aristada (at the chosen dose) on the same day or within 10 days
This collapses the standard 21-day oral overlap into essentially one day, which is particularly useful at the end of a hospital admission. This regimen is sometimes referred to as the "Aristada Initio bridge."
Missed-dose protocols
The FDA labelling defines catch-up protocols depending on how many weeks have passed since the last injection. For very late doses, a fresh oral aripiprazole bridge or repeat use of Aristada Initio may be required. Specific catch-up plans belong to the prescriber.
Call the clinic. The catch-up protocol for Aristada is more nuanced than for some other LAIs because of the multiple dosing intervals. Don't try to manage this on your own.
Side effects
The side effect profile is essentially the same as oral aripiprazole and Abilify Maintena:
- Akathisia — internal restlessness, the most common aripiprazole side effect
- Insomnia, particularly early in treatment
- Headache
- Modest weight gain — typically less than other antipsychotics
- Hyperprolactinaemia is uncommon with aripiprazole
- Compulsive behaviours (gambling, shopping, eating, sexual) — a class effect of dopamine partial agonists
Injection-site reactions
Aristada injections are larger volume than some other LAIs, and injection-site discomfort is common — pain, swelling, occasional bruising. Most resolves within a few days. Persistent nodules are uncommon but can occur.
Aristada vs Abilify Maintena
Both are aripiprazole-based LAIs. Some key differences:
- Dosing interval flexibility — Aristada offers monthly, every-6-week, and every-2-month options; Abilify Maintena is monthly only
- Initiation — Maintena uses 14-day oral overlap; Aristada uses 21-day oral overlap or the Aristada Initio one-day regimen
- Active drug — Aristada is a prodrug (aripiprazole lauroxil); Maintena is aripiprazole monohydrate. Pharmacologically the active metabolite is the same in both.
- Dose form — Aristada is a fat-soluble suspension; Maintena is a water-based suspension
The choice is often driven by dosing interval preference, prior tolerance, and clinician familiarity.
Who Aristada fits well
- Patients who tolerate aripiprazole well and want a long dosing interval
- Patients leaving the hospital where the Aristada Initio bridge is useful
- Patients who prefer 6-weekly or every-2-month visits over monthly
Who might want alternatives
- Patients with severe akathisia on oral aripiprazole
- Patients in whom rapid dose adjustment is needed (oral medications are more flexible)
- Patients with active compulsive behaviour issues triggered by aripiprazole
The bigger picture
Aristada's value proposition is flexibility. With three dosing intervals and a one-day initiation option, it offers more choice than most other LAIs — at the cost of slightly more complex dosing decisions. For patients who want the metabolic profile of aripiprazole and the longest possible interval between injections, it is one of the strongest options on the market.
This article is for educational purposes only and is not medical advice. Information is summarised from publicly available FDA labelling and peer-reviewed literature. Always consult your prescribing clinician before starting, stopping, or changing any medication. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.